Evidence map›Paper›PMID 36824414›Full record

ArticleInternational journal of nanomedicine2023

Topical Delivery of ROS-Responsive Methotrexate Prodrug Nanoassemblies by a Dissolvable Microneedle Patch for Psoriasis Therapy.

Yong Zhou, Lei Yang, Yifu Lyu, Di Wu, Ying Zhu, Jingjing Li, Dabo Jiang, Xiaofei Xin, Lifang Yin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06555497 (A Pilot Study of Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Mild-moderate Plaque-type Psoriasis), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06555497 early_phase1completednot on this map

A Pilot Study of Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Mild-moderate Plaque-type Psoriasis

TypeinterventionalSponsorDr. Jose N. Rodriguez Memorial Hospital and SanitariumRan2022 to 2023Enrolled2ConditionsPilot Study, PsoriasisArmstopical 1% methotrexate gel, clobetasol propionate 0.05% ointment
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yong Zhou *Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Lei Yang *Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Yifu Lyu *Department of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.ORCID 0000-0001-7971-138X
Di WuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Ying ZhuDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Jingjing LiDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Dabo JiangDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Xiaofei XinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
Lifang YinDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, People's Republic of China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Oxidative stress, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and adenosine signaling are factors associated with psoriatic inflammation. Topical delivery of methotrexate (MTX) has become an option to overcome the side effects caused by systemic therapy in psoriasis, leading to the suppression of NF-κB activation through boosting adenosine release. However, thickened psoriatic skin is the primary restriction against local drug delivery. Methods: In this study, a ROS responsive MTX prodrug (MTX-TK-HA) was synthesized with the feature of CD44 mediated active targeting to hyperproliferative keratinocytes. MTX prodrug and PLA-mPEG were formulated by nano-precipitation method to develop the MTX-TK-HA/PLA-mPEG nanoassemblies. To achieve painless transdermal delivery, a dissolving microneedle was applied for direct loading of these nanoassemblies by micromolding technique. The particle size, zeta potential, ROS-responsiveness, permeability, and mechanical strength of nanoassemblies and microneedle arrays were determined, respectively. Then, MTT assay, immunoblot analysis, ELISA assay, flow cytometry, and histological staining were utilized to thoroughly evaluate the efficacy of nanoassemblies-loaded microneedles in an imiquimod-induced psoriatic mouse model. Results: Nanoassemblies-loaded microneedle arrays were capable of significantly penetrating imiquimod-induced psoriatic epidermis in mice. The efficient topical delivery of these nanoassemblies was achieved by potent mechanical strength and hyaluronic acid as the dissolvable matrix for microneedle arrays. CD44-mediated endocytosis enabled the intracellular uptake of nanoassemblies in keratinocytes, and methotrexate was released from MTX-TK-HA with ROS stimuli, followed by suppressing the proliferation of epidermal cells via NF-κB pathway blockade. Conclusion: In a psoriatic mouse model, nanoassemblies loaded microneedle arrays relieve inflammatory skin disorders via regulation of adenosine and NF-κB signaling. Our study offered a rational design for the transdermal delivery of hydrophobic agents and defined an effective therapeutic option for psoriasis treatment.

Indexed as

ProdrugsPsoriasisAnimalsImiquimodMethotrexateMiceNF-kappa BPolyestersPolyethylene GlycolsReactive Oxygen SpeciesSkinImiquimodMethotrexatemonomethoxypolyethylene glycolNF-kappa BPolyestersPolyethylene GlycolsProdrugsReactive Oxygen SpeciesmethotrexatemicroneedlepsoriasisROS-responsivenesstopical delivery

Identifiers

PMID36824414
PMCPMC9941683
OpenAlexW4321332913

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.